Aurora Germany and Grow Group have extended their long-standing strategic relationship by signing a two-year market access services agreement for the UK. 

"We are delighted to extend our existing strategic relationship with Grow," stated Miguel Martin, Chief Executive Officer of Aurora Cannabis. "We have worked successfully with Grow and their joint venture partner, IPS, since entering the UK market. Renewing this agreement will help to broaden access for patients by leveraging Grow's work educating physicians and creating awareness of medical cannabis options. Aurora is committed to providing access to legally produced high-quality pharmaceutical-grade medical cannabis to address the needs of the growing European medical cannabis market, made possible with our EU GMP facility, Aurora Nordic."

"Everything we do is with the patient in mind. Addressing patients' needs and broadening access to medical cannabis in the UK is at the heart of Grow's strategy," said Pierre van Weperen, Managing Director of Grow Group PLC, UK & Ireland. "Quality of products, broad range of offerings and a strong supply chain is critical to serving the UK's fast-growing patient population. Partnering with companies like Aurora will continue to enable us to offer a portfolio of high-quality flowers and extracts to doctors and the patients who will benefit from them. Every day, these products make a difference for patients and we look forward to advancing market access together with Aurora."

For more information: